A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19–positive patients with cancer

Florian Scotté; Etienne Minvielle; Olivier Mir; Fabrice André; Fabrice Barlesi; Jean Charles Soria

doi:10.1016/j.ejca.2020.03.020

A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19–positive patients with cancer

Florian Scotté, Etienne Minvielle, Olivier Mir, Fabrice André, Fabrice Barlesi, Jean Charles Soria

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

20 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	1-4
Nombre de pages	4
journal	European Journal of Cancer
Volume	132
Les DOIs	https://doi.org/10.1016/j.ejca.2020.03.020
état	Publié - 1 juin 2020

Accès au document

10.1016/j.ejca.2020.03.020

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{4e344b983feb4cabbe04c82afd71b23d,

title = "A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19–positive patients with cancer",

author = "Florian Scott{\'e} and Etienne Minvielle and Olivier Mir and Fabrice Andr{\'e} and Fabrice Barlesi and Soria, {Jean Charles}",

note = "Funding Information: F.S. reports personal fees from Helsinn, personal fees from MSD, personal fees from Roche, personal fees from Amgen, personal fees from Pierre Fabre Oncology, personal fees from Pfizer, personal fees from Mundipharma, personal fees from Mylan and personal fees from Leo Pharma, outside the submitted work; E.M. has no disclosure to declare. O.M. reports personal fees from Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Eli Lilly, Incyte, Ipsen, Lundbeck, MSD, Novartis, Pfizer, Roche, Servier and Vifor Pharma and other fees from Amplitude Surgical, Ipsen and Transgene, outside the submitted work; F.A. has no disclosure to declare. F.B. reports personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer and Takeda, outside the submitted work; J.-C.S. reports feesconsultancy fees from AstraZeneca, Astex, Clovis, GSK, GamaMabs, Lilly, MSD, Mission Therapeutics, Merus, Pfizer, PharmaMar, Pierre Fabre, Roche-Genentech, Sanofi, Servier, Symphogen and Takeda, is a full-time employee for AstraZeneca between September 2017 and December 2019, reports other fees from the shareholder Gritstone, during the conduct of the study, and reports personal fees from null, outside the submitted work.",

year = "2020",

month = jun,

day = "1",

doi = "10.1016/j.ejca.2020.03.020",

language = "English",

volume = "132",

pages = "1--4",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

TY - JOUR

T1 - A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19–positive patients with cancer

AU - Scotté, Florian

AU - Minvielle, Etienne

AU - Mir, Olivier

AU - André, Fabrice

AU - Barlesi, Fabrice

AU - Soria, Jean Charles

N1 - Funding Information: F.S. reports personal fees from Helsinn, personal fees from MSD, personal fees from Roche, personal fees from Amgen, personal fees from Pierre Fabre Oncology, personal fees from Pfizer, personal fees from Mundipharma, personal fees from Mylan and personal fees from Leo Pharma, outside the submitted work; E.M. has no disclosure to declare. O.M. reports personal fees from Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Eli Lilly, Incyte, Ipsen, Lundbeck, MSD, Novartis, Pfizer, Roche, Servier and Vifor Pharma and other fees from Amplitude Surgical, Ipsen and Transgene, outside the submitted work; F.A. has no disclosure to declare. F.B. reports personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer and Takeda, outside the submitted work; J.-C.S. reports feesconsultancy fees from AstraZeneca, Astex, Clovis, GSK, GamaMabs, Lilly, MSD, Mission Therapeutics, Merus, Pfizer, PharmaMar, Pierre Fabre, Roche-Genentech, Sanofi, Servier, Symphogen and Takeda, is a full-time employee for AstraZeneca between September 2017 and December 2019, reports other fees from the shareholder Gritstone, during the conduct of the study, and reports personal fees from null, outside the submitted work.

PY - 2020/6/1

Y1 - 2020/6/1

UR - http://www.scopus.com/inward/record.url?scp=85083004861&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2020.03.020

DO - 10.1016/j.ejca.2020.03.020

M3 - Letter

C2 - 32294611

AN - SCOPUS:85083004861

SN - 0959-8049

VL - 132

SP - 1

EP - 4

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -